Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study
Publication/Presentation Date
5-2013
Volume
31
Issue
15
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS